Today, a Director at Lipocine (LPCN), John Higuchi, sold shares of LPCN for $9,028.
Following John Higuchi’s last LPCN Sell transaction on March 18, 2020, the stock climbed by 1.0%.
See today’s analyst top recommended stocks >>
LPCN’s market cap is $89.33 million and the company has a P/E ratio of -3.10. The company has a one-year high of $2.39 and a one-year low of $0.30.
John Higuchi’s trades have generated a 122.0% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Lipocine, Inc. operates as a pharmaceutical company, which engages in the research and development of treatment for use in men’s and women’s health through proprietary drug delivery technologies. It focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded in 2011 and is headquartered in Salt Lake City, UT.
